Blood Test Tracks Alzheimer's Drug Response Early
Researchers are testing whether blood-based circular RNA markers can show if an early-stage Alzheimer's treatment is working.
Updated on Nov. 5, 2026 in Alzheimer’s
PharmatrophiX has entered a strategic collaboration with Circular Genomics to apply blood-based circular RNA biomarker profiling to LM11A-31, an investigational Alzheimer's drug candidate. The initial work is intended to inform the drug's development path and could extend to other neurodegenerative programmes.
Why it matters
Alzheimer's drug development has long lacked reliable blood-based markers that show whether a treatment is reaching its biological target, so a more measurable approach could help researchers judge early whether a candidate is working. The collaboration combines a neurotrophin-receptor drug with a new class of molecular biomarkers at a time when the field is looking for ways to speed up and sharpen its trials.
This is an announced research partnership rather than a study, so no trial size, duration, or measured effect has been reported. The companies describe the work as a planned exploration of baseline molecular differences and pathway changes during treatment, not as a demonstrated result.
The players
PharmatrophiX
A drug developer working on neurodegenerative treatments, including the p75 neurotrophin receptor programme that LM11A-31 belongs to.
Circular Genomics
A company that develops molecular profiling tools based on circular RNA, including its CircPath system, for biomarker research.
The details
LM11A-31 is a first-in-class small molecule that acts on the p75 neurotrophin receptor, a cell-surface protein involved in how nerve cells respond to survival and stress signals. Circular RNAs are looped RNA molecules that are unusually stable and can be found in blood, which makes them candidates for biomarkers. Under the collaboration, Circular Genomics will use its research-use-only CircPath profiling system to look for differences between patients at the start of treatment and to track how biological pathways shift over time. The companies plan to pair these circRNA findings with cognitive, clinical, imaging, proteomic, and Alzheimer's biomarker measures to better understand how the drug affects patient biology.
Timeline
November 5, 2026: PharmatrophiX and Circular Genomics announced the collaboration.
Health Landscape
Alzheimer's treatment research has increasingly focused on measuring whether drugs reach their intended biological targets, not only on long clinical trials. Blood-based biomarkers are one route the field is pursuing to make that measurement practical and less invasive.
For now this is early-stage research with no direct change to care, so there is nothing to act on for treatment or testing. If you or a family member are navigating memory concerns, it is worth discussing current diagnostic options and any clinical trials you may be eligible for with a physician or neurologist.
The takeaway
Blood-based biomarkers could eventually make it easier to see whether Alzheimer's drugs are working, but this collaboration is an early step rather than a clinical result. Readers interested in the field can ask their physician about how current memory assessments and research studies are evaluated.
Further reading
For more on the disease at the centre of this research, see our Alzheimer’s coverage.
Source note: This article includes information reported by Pharmaceutical Technology.
